BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND PER1, O15534, 5187, ENSG00000179094, RIGUI AND Treatment
15 results:

  • 1. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
    Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
    Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. "Time" for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment.
    Miro C; Docimo A; Barrea L; Verde L; Cernea S; Sojat AS; Marina LV; Docimo G; Colao A; Dentice M; Muscogiuri G
    Semin Cancer Biol; 2023 Jun; 91():99-109. PubMed ID: 36893964
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Disrupting Circadian Rhythm via the per1-HK2 Axis Reverses Trastuzumab Resistance in Gastric cancer.
    Wang J; Huang Q; Hu X; Zhang S; Jiang Y; Yao G; Hu K; Xu X; Liang B; Wu Q; Ma Z; Wang Y; Wang C; Wu Z; Rong X; Liao W; Shi M
    Cancer Res; 2022 Apr; 82(8):1503-1517. PubMed ID: 35255118
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Chronoradiobiology of breast cancer: The Time Is Now to Link Circadian Rhythm and Radiation Biology.
    Nelson N; Lombardo J; Matlack L; Smith A; Hines K; Shi W; Simone NL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163264
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
    Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
    Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
    Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
    Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
    Wolf DM; Jordan VC
    Breast Cancer Res Treat; 1994; 31(1):129-38. PubMed ID: 7981453
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
    Wolf DM; Jordan VC
    Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. breast lymphoma. A B-cell spectrum including the low grade B-cell lymphoma of mucosa associated lymphoid tissue.
    Mattia AR; Ferry JA; Harris NL
    Am J Surg Pathol; 1993 Jun; 17(6):574-87. PubMed ID: 8333556
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
    Gottardis MM; Jiang SY; Jeng MH; Jordan VC
    Cancer Res; 1989 Aug; 49(15):4090-3. PubMed ID: 2743303
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.